News Briefs

The state budget recently unveiled by New York Gov. Andrew Cuomo (D) would delay the state’s move to carve out pharmacy benefits from its Medicaid managed care contracts, Modern Healthcare reported. Instead of starting April 1 of this year, the passed health budget bill would make the change no earlier than April 1, 2023. The New York Health Plan Association has been vocal in its opposition to the move, claiming it could thwart care coordination efforts by plans (RDB 1/28/21, p. 1). Read more at https://bit.ly/2QlSQue.

An analysis by Blues affiliate- owned PBM Prime Therapeutics found that an average course of chimeric antigen receptor T-cell (CAR-T) therapies for B-cell lymphoma cost $700,000, and in some cases exceeded $1 million. The analysis reviewed records from 74 members, and found that 39% of patients did not have a “durable CAR-T response, with chemotherapy being the most [subsequent] common event (30%) and 1 in 20 going on to have a bone marrow transplant.” Read more at https://bit.ly/2QdmJNn.

© 2022 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

workers-prepping-infusion-drug
May 12

Major PBMs Look Ahead to 2023 for Biosimilars Boom

READ MORE
wall-street-sign
May 12

Centene Plans to Sell Magellan Rx, PANTHERx Rare for $2.8 Billion

READ MORE
pills-and-dollars
May 12

Study: With High Prices, Rebate Revenue Is Growing for PBMs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today